Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2026.

PARENTERALS Date: 11.08.2026 The Manager The Manager BSE Limited NSE Limited P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SATPARENT) Unit: Sai Parenteral’s Limited Sub: Outcome of Board Meeting held on Tuesday, 11 August, 2026 With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenteral’s Limited held on Tuesday. the 11% day of August, 2026 at 11:00 a.m. at the Registered Office of the Company considered and approved the following: Un-audited financial results (Standalone and Consolidated) for the quarter ended June 30, 2026. 2. Limited Review Report (Standalone and Consolidated) for the quarter ended June 30, 2026. 3. Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as Director of the Company, Retiring by rotation. (Details are attached as Annexure A) 4. Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as the Managing Director of the Company for a period of 3 years w.e.f.,, 01.01.2027, subject to approval of shareholders. (Details are attached as Annexure A) 5. Re-appointment of Mrs. Vijitha Gorrepati (DIN:03492979) as the Whole-time Director of the Company for a period of 3 years w.e.f., 01.01.2027, subject to approval of shareholders. (Details are attached as Annexure A) 6. Appointment of Mr. Kunal Kakumanu (DIN:11281388) as Additional and Executive Director of the Company for a period of 3 years w.e.f., 11.08.2026, subject to approval of shareholders. (Details are attached as Annexure A) 7. Resignation of the Ms. Shivali Aggarwal as Company Secretary & Compliance Officer of the Company on or before 12.10.2026. (Details attached as Annexure B) (Resignation Letter enclosed) 8. Resignation of the Mrs. Aruna Karusala (DIN:01673731) as Non-Executive Director of the Company w.e.f.,11.08.2026. (Details attached as Annexure B) (Resignation Letter enclosed) 9. Variation in the objects and/or terms of utilisation of the IPO proceeds and extension of the time period for utilisation of the IPO proceeds as disclosed in the prospectus dated march 28, 2026, relating to objects (a) Capacity expansion and upgradation of manufacturing facilities and (b) Establishment of a research & development centre, subject to approval of shareholders. SAI PARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frormmemmem— mail: infoesaiparontorals.c(o©m 1917997991306 Email: info@sail torals + PARENTERALS A. Acquisition of Green field Injectables manufacturing plant by acquiring 60% of Equity Shares in Saicriti Pharma Private Limited in lieu of Upgradation of Unit I and Unit IT under the Object of Upgradation of Manufacturing Facilities The amount of Rs. 838.34 million, originally earmarked in the Prospectus towards the upgradation of Unit I and Unit II to achieve compliance with European Union Good Manufacturing Practices (EU-GMP) and thereby cater to the significant demand for its injectable products in international markets, shall now be utilised towards the acquisition of 60% of the equity shares of Saicriti Pharma Private Limited, which is developing a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, the development of which entails a total estimated cost of _Rs. 2,149.60 million. The proposed acquisition will enable the Company to achieve the same strategic objectives through an alternative implementation mechanism. (Brief Details attached as Annexure C) B. Acquisition of existing R& Facility by acquiring 60% of the Equity Shares in Prathyak Laboratories Private Limited as an alternative to the establishment of the proposed Research & Development Centre The amount of Rs.180.23 million originally earmarked for establishment of a new Research & Development Centre shall now be utilised towards acquisition of a 60% equity shares in Prathyak Laboratories Private Limited. Instead of establishing a greenfield R&D facility, the Company proposes to acquire an established pharmaceutical research and development platform, which is expected to achieve the same strategic objectives within a shorter timeframe, with a product portfolio of 124 products development, with lower execution risk and enhanced operational capabilities. (Brief Details attached as Annexure C) 10. Ratification of the Sai Parenterals Limited Employee Stock Option Plan, 2025 (ESOP Scheme- 2025), subject to approval of shareholders. 11. Ratification of the extension of benefits of the Sai Parenteral’s Limited employee stock option plan 2025 (“ESOP Scheme - 2025”) to the subsidiary companies, subject to approval of shareholders. 12. Incorporation of a New Step-Down Subsidiary of Company in the United States of America: Incorporation of a New Company in the United States of America as a Wholly Owned Subsidiary of Sai Parenterals Pte. Ltd., Singapore, Wholly Owned Subsidiary of the Company. (Brief Details attached as Annexure D) 13. The Material Related Party Transaction of the Company in respect of the grant of a loan to Sai Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals pty. Limited, Australia, Step down subsidiary, subject to approval of shareholders. 14. The Material Related Party transaction of the Company with Noumed Pharmaceuticals Pty. Limited, step-down subsidiary Company for the FY 2026-27 for sale of goods and/or services, subject to approval of shareholders. SAI PARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frormmemmem— mail: infoesaiparontorals.c(o©m 1917997991306 Email: info@sail torals + PARENTERALS 15. Notice of the Annual General Meeting (AGM) the Directors’ Report along with the Annexures thereto, the Management Discussion and Analysis Report (MD&A) and the Corporate Governance Report for the Financial Year ended 31.03.2026. 16. Annual General Meeting for the FY 2025-26 is scheduled to be held on Thursday, 10® September, 2026 at 11:00 a.m. through Video Conferencing (“VC”)/ other Audio-Visual Means (“OAVM”). 17. Reconstitution of the composition of the Committees of the Board with effect from today, 11% August, 2026. (Details are attached as Annexure E) 18. Reconstitution of POSH Committee under the Prevention of Sexual Harassment (POSH) Act. (Details are attached as Annexure F) The Meeting concluded at 05:00 pm. This is for the information and records of the Exchanges, please. Thanking you. Yours sincerely, For Sai Parenterals Limited Anil Kumar Karusala Managing Director (DIN- 01866646) SAI PARENTERALS www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032. frvrmmemm—— mail: infoesaiparontorals.c(o©m 1917997991306 Email: info@sail torals + PARENTERALS Annexure —A [Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD- 2/P/CIR/2026/1 dated January 30, 2026)] Particulars Anil Kumar Karusala Vijitha Gorrepati Kunal Kakumanu (DIN: 01866646) (DIN: 03492979) (DIN: 11281388) Reason for change viz. | Re-appointment of Mr. | Re-appointment of Mrs. | Appointment of Mr. appointment, resignation, | Anil Kumar Karusala as | Vijitha Gorrepati as Whole- | Kunal ~Kakumanu as removal, death or | Managing Director of the | Time Director of the | Executive Director of the otherwise company. company. company. Date of appointment & | Re-appointment of Mr. Anil | Reappointment of Mrs. | Appointment of Mr. Terms of appointment Kumar Kamsala (DIN: | Vijitha Gorrepati (DIN: | Kunal Kakumanu 01866646) as Managing | 03492979) as Executive | (DIN:11281388) as Director of the Company for a | Director of the Company fora | Executive Director of the period oft hree (3) years with | period of three (3) yea [Showing first 8,000 characters — download PDF for full document]